Pusceddu S, et al. - The tie-up between glycemia and progression-free survival (PFS) of patients with neuroendocrine tumors (NETs) treated with everolimus and/or somatostatin analogues was comprehensively analyzed by researchers. They also gauged the correlation between metformin use and PFS time at 24 medical centers in Italy, from 1999 through 2015. It was deduced that PFS of patients treated with metformin was considerably longer than for patients without diabetes and longer than for patients with diabetes receiving other treatments. Therefore, a prominent link was brought to light between metformin use and longer PFS.